Pulmonary Fibrosis Foundation Applauds The Food And Drug Administration's (FDA) Prompt Decision To Approve EsbrietÂ® (pirfenidone) And OFEVÂ® (nintedanib) For The Treatment Of Idiopathic Pulmonary Fibrosis